// App-Quantinova.ai

: Ocular Adverse Events in Transplant Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Belantamab Mafodotin, Lenalidomide, and Dexamethasone in a Phase 1/2 Trial

Researchers

Presenter

  • Evangelos Terpos

Principal Investigators

  • Ioannis Ntanasis-Stathopoulos

  • Maria Gavriatopoulou

  • Panagiotis Malandrakis

  • Despina Fotiou

  • Nikolaos Kanellias

  • Magdalini Migkou

  • Foteini Theodorakakou

  • Vasiliki Spiliopoulou

  • Rodanthi Syrigou

  • Evangelos Eleutherakis Papaiakovou

  • Stavros Gkolfinopoulos

  • Kyriaki Manousou

  • Efstathios Kastritis

  • Meletios A. Dimopoulos

Medical Centers

  • Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Athens, Greece

  • Health Data Specialists, Dublin, Ireland

Locations

  • Greece

  • Ireland

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Ophthalmology (OP)

Disease

  • Multiple Myeloma

  • Dry Eye Syndrome

Biomarkers

  • N/A

Drug/Treatment

  • GSK2857916

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • Lenalidomide

Outcome

  • N/A

Study Design

  • Randomized

  • Safety

  • Open Label

  • Tolerability

  • Prospective

  • Cohort

Phase

  • I/II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved